PALI

Company Overview — What Does PALISADE BIO, INC. Do?

Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress caused by reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California. PALISADE BIO, INC. (PALI) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO J. D. Finley and employs approximately 10 people, headquartered in GERMANTOWN, California. With a market capitalization of $312M, PALI is one of the notable companies in the Healthcare sector.

PALISADE BIO, INC. (PALI) Stock Rating — Hold (April 2026)

As of April 2026, PALISADE BIO, INC. receives a Hold rating with a composite score of 30.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.PALI ranks #1,683 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PALISADE BIO, INC. ranks #158 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PALI Stock Price and 52-Week Range

PALISADE BIO, INC. (PALI) currently trades at $2.00. The stock gained $0.02 (1.0%) in the most recent trading session. The 52-week high for PALI is $2.64, which means the stock is currently trading -24.2% from its annual peak. The 52-week low is $0.53, putting the stock 277.4% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is PALI Overvalued or Undervalued? — Valuation Analysis

PALISADE BIO, INC. (PALI) carries a value factor score of 27/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.47x, versus the sector average of 2.75x.

At current multiples, PALISADE BIO, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PALISADE BIO, INC. Profitability — ROE, Margins, and Quality Score

PALISADE BIO, INC. (PALI) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -8.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -8.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PALI Debt, Balance Sheet, and Financial Health

PALISADE BIO, INC. has a debt-to-equity ratio of 4.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 28.95x, indicating strong short-term liquidity. Total debt on the balance sheet is $211,000. Cash and equivalents stand at $5M.

PALI has a beta of 0.67, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for PALISADE BIO, INC. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

PALISADE BIO, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PALISADE BIO, INC. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-11M. Operating income came in at $-12M.

In FY 2025, PALISADE BIO, INC. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-17M. Operating income came in at $-18M.

In Q3 2025, PALISADE BIO, INC. reported revenue of $0 and earnings per share (EPS) of $-0.38. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2025, PALISADE BIO, INC. reported revenue of $0 and earnings per share (EPS) of $-0.58. Net income for the quarter was $-3M. Operating income came in at $-3M.

Over the past 8 quarters, PALISADE BIO, INC. has experienced revenue contraction from $0 to $0. Investors analyzing PALI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PALI Dividend Yield and Income Analysis

PALISADE BIO, INC. (PALI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PALI Momentum and Technical Analysis Profile

PALISADE BIO, INC. (PALI) has a momentum factor score of 60/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PALI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PALISADE BIO, INC. (PALI) ranks #158 out of 838 stocks based on the Blank Capital composite score. This places PALI in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PALI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PALI vs S&P 500 (SPY) comparison to assess how PALISADE BIO, INC. stacks up against the broader market across all factor dimensions.

PALI Next Earnings Date

No upcoming earnings date has been announced for PALISADE BIO, INC. (PALI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PALI? — Investment Thesis Summary

PALISADE BIO, INC. presents a balanced picture with arguments on both sides. The quality score of 20/100 flags below-average profitability. The value score of 27/100 indicates premium valuation. Price momentum is positive at 60/100, suggesting the trend favors buyers. High volatility (stability score 31/100) increases portfolio risk.

In summary, PALISADE BIO, INC. (PALI) earns a Hold rating with a composite score of 30.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PALI stock.

Related Resources for PALI Investors

Explore more research and tools: PALI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PALI head-to-head with peers: PALI vs AZN, PALI vs SLGL, PALI vs VMD.